QuidelOrtho Co. (NASDAQ:QDEL – Get Free Report) has been given an average rating of “Buy” by the five research firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $124.60.
Several equities analysts have recently issued reports on the stock. JPMorgan Chase & Co. lowered their target price on shares of QuidelOrtho from $91.00 to $85.00 and set a “neutral” rating for the company in a report on Wednesday, August 9th. Raymond James lowered their target price on shares of QuidelOrtho from $110.00 to $100.00 and set a “strong-buy” rating for the company in a report on Thursday. Royal Bank of Canada reiterated an “outperform” rating and set a $140.00 target price on shares of QuidelOrtho in a report on Tuesday, September 19th. StockNews.com assumed coverage on shares of QuidelOrtho in a report on Thursday, October 5th. They set a “hold” rating for the company. Finally, William Blair reiterated an “outperform” rating on shares of QuidelOrtho in a report on Thursday.
Institutional Investors Weigh In On QuidelOrtho
QuidelOrtho Stock Performance
Shares of QDEL opened at $64.27 on Thursday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.59 and a quick ratio of 0.97. QuidelOrtho has a one year low of $59.29 and a one year high of $102.00. The company has a 50-day simple moving average of $71.63 and a two-hundred day simple moving average of $80.29. The firm has a market capitalization of $4.29 billion, a PE ratio of 338.28 and a beta of 0.33.
QuidelOrtho (NASDAQ:QDEL – Get Free Report) last issued its quarterly earnings data on Wednesday, November 1st. The company reported $0.90 EPS for the quarter, topping the consensus estimate of $0.44 by $0.46. QuidelOrtho had a net margin of 0.42% and a return on equity of 6.31%. The business had revenue of $744.00 million during the quarter, compared to analyst estimates of $691.90 million. During the same period last year, the business posted $1.83 earnings per share. QuidelOrtho’s quarterly revenue was down 5.1% compared to the same quarter last year. On average, analysts anticipate that QuidelOrtho will post 4.86 EPS for the current fiscal year.
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies and solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.
- Five stocks we like better than QuidelOrtho
- How to Use the MarketBeat Stock Split Calculator
- MarketBeat Week in Review – 10/30 – 11/3
- 3 Warren Buffett Stocks to Buy Now
- Shocking uranium play that hedge funds kept hidden
- Breakout Stocks: What They Are and How to Identify Them
- Dependable dividends: Why utility stocks are on fire
Receive News & Ratings for QuidelOrtho Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QuidelOrtho and related companies with MarketBeat.com's FREE daily email newsletter.